To learn more about planned accredited symposia,
check out these videos with more details below.

Co-developed with Janssen Canada

To Cut a Long Story Short: How early advanced psoriasis treatment can prevent long-term complications

Join us in an exciting panel discussion on some of the hottest and provocative topics in psoriasis!

This all-female panel of Canadian experts will explore psoriasis as a chronic, systemic disease with progressive elements by exploring a complex case in skin of colour. Discussion will focus on identification of appropriate patients for early advanced therapies to prevent complications and poor outcomes associated with inadequate treatment and longer active disease duration. You will need your mobile device during this presentation to participate in pre- and post-symposium polling questions, including knowledge-based questions, clinical judgement questions, and questions about what you may change in your practice in the future! Join us on June 22 at 8 am!


Kerri S. Purdy, MD, FRCPC, Halifax, NS


Alexandra Mereniuk, MD, FRCPC, Montreal, QC
Geeta Yadav, MD, MHS, FRCPC, Toronto, ON
Marissa Joseph, MSc, MD, FRCPC (Pediatrics) FRCPC (Dermatology), Toronto, ON

Learning objectives:

After this session, participants will be better able to recognize severe psoriasis across diverse patients through their experience of the disease; describe psoriasis as a chronic, systemic disease with progressive elements and the consequences of inadequate disease control; and identify patients who will benefit from earlier treatment with the advanced therapies.

Co-developed with Pfizer Inc.

Not all Flares are Red; Disparities in Skin Conditions for Patients with Skin of Color

More than one-fifth of Canadians have richly pigmented skin. There are disparities in the diagnosis and treatment of dermatologic conditions in diverse skin types due to a lack of education, training, and confidence in treating conditions affecting people with skin of colour. Through a series of patient cases and ‘What If’ scenarios led by a diverse and multidisciplinary faculty, this symposium will identify how variations in skin tone can alter diagnosis; and incorporate practical treatment tips and key communication points when educating patients with skin of colour who live with atopic dermatitis, alopecia areata, and vitiligo. The impact these diseases have on the quality of life in these patient populations will be heard and discussed amongst expert panel presenters.


Marissa Joseph, MD, FRCPC (Dermatology), FRCPC (Pediatrics), Toronto, ON


Andrew Alexis, MD, MPH (Dermatology), New York City, NY, USA
Rachel Asiniwasis, MD, FRCPC, DABD (Dermatology), Regina, SK
Vipul Jain, MB BS, FRCPC (Allergy and Clinical Immunology), Niagara Falls, ON

Learning Objectives

At the end of this symposium, participants will be able to discuss differences in clinical presentation of inflammatory skin conditions across diverse skin types; recognize treatment pearls and key communication points when treating skin of color patients with atopic dermatitis, hair disorders and vitiligo; and describe the quality of life impact in patients with skin of colour, including culturally competent care and interdisciplinary HCP engagement.

Co-developed with Bristol Myers Squibb Canada

Rumble in the Jungle: Duking out TYK2 inhibition in psoriatic disease

Ladies and gentlemen, welcome to our symposium, featuring two worthy debaters. Towering in at 6ft 4in, is our first debater Dr. Mark Kirchhof, who will support the position that TYK2 inhibitors are the same as other JAK inhibitors. On the left, wearing a purple sport coat, is our second debater, Dr. Kim Papp who will support the position that TYK2 inhibitors are different from other JAK inhibitors. Our debate features 4 rounds, addressing unmet needs for novel oral therapies and debating the merits of targeting TYK2 in psoriatic disease. The debate will be refereed by Dr. Vim Prajapati and judged by audience members and Dr. Irina Turchin, using interactive polling throughout to emphasize learning points and determine the strongest arguments. Let’s get ready to rumble!


Kim Papp, MD, PhD, FRCPC, Waterloo, ON
Mark Kirchhof, MD, PhD, FRCPC, FAAD, Ottawa, ON
Irina Turchin, MD, FRCPC, DABD, FAAD, Fredericton, NB
Vimal Prajapati, MD, FRCPC, FAAD, Calgary, AB

Learning Objectives

At the end of this symposium, participants will be able to explain the differences in mechanism of actions between TYK2 inhibitors, JAK1-3 inhibitors and other small molecule therapies; eescribe the clinical relevance of pharmacodynamics of molecules targeting the JAK-STAT pathway in psoriatic disease; and communicate important safety and efficacy considerations related to TYK2 inhibitors in relation to JAK inhibitors and other small molecule therapies for psoriasis and apply these skills in clinical practice.

Co-developed with Galderma Canada Inc.

More than just itch: Putting IL-31 at the center of neuroimmune interaction in atopic dermatitis and prurigo nodularis

This symposium outlines the latest innovative advances in our understanding of the inflammatory pathways in immunological skin conditions. The expert faculty of international and national speakers will discuss the burden of atopic dermatitis (AD) and prurigo nodularis (PN) and their pathophysiology, and how these insights have led to new avenues in immunomodulation. Interleukin-31 (IL-31) is a highly expressed neuroimmune cytokine in chronic inflammatory skin conditions like AD and PN that acts as a central mediator to drive the itch, inflammation, skin barrier disruption, and tissue remodelling in patients with AD or PN. Targeting IL-31 signaling aims to decrease pruritus and signs of skin inflammation, which may result in reduced severity of AD and PN and improved patient quality of life.


Kim Papp, MD, PhD, FRCPC, Waterloo, ON
Chih-ho Hong, MD, FRCPC, Surrey, BC

Learning Objectives

Presentation 1: You should be able to discuss the heterogeneous phenotypes of AD and symptom fluctuation over time; describe the specific burden of AD symptoms on patients’ quality of life and wellbeing; discuss the unmet needs for patients with AD and how these may be addressed by new drugs in development; and recognize IL-31 as a major contributor to multiple core disease aspects in AD pathophysiology. 

Presentation 2: You should be able to diagnose and differentiate PN as a distinct and independent disease; recognize the specific burden of PN for patients; be aware of the unmet needs for PN patients and how these may be addressed by new drugs in development; and understand the role of  IL-31 as a major contributor to multiple core disease aspects in PN pathophysiology.

Co-developed with La Roche-Posay

Review and update on dermoscopy: for beginners to advanced dermoscopists

Dermoscopy is an essential technique used by every dermatologist and dermatology resident in their daily practice. This interactive session is directed to dermoscopists of all levels. A variety of instructive cases of pigmented and non-pigmented lesions will be presented in a quiz format. A Brief description of some dermoscopic criteria and algorithms for melanocytic and non-melanocytic lesions will be presented. Cases to illustrate new dermoscopic signs will also be discussed. Attendees will be able to participate during the session and share their interests and knowledge in this essential diagnostic tool.


Joël Claveau, MD, CSPQ, FRCPC, DABD, Québec, QC
Jean-François Sei, MD, Saint-Germain-en-Laye, France
Jacques Savary, MD, Paris, France